Dr. Grossmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Rahway -
Princeton, NJ 08540Phone+1 801-865-2334
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2007 - 2009
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2006 - 2007- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2004 - 2006
Oregon Health and Science University School of MedicineClass of 2004
Certifications & Licensure
OR State Medical License 2023 - 2025
UT State Medical License 2007 - 2024
FL State Medical License 2018 - 2020- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver Start of enrollment: 2008 Jul 01
- Radiation Use During Vemurafenib Treatment Start of enrollment: 2017 Jun 01
- Vemurafenib:Radiation Use During Vemurafenib Treatment Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 59 citationsPrognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical BenefitDouglas Grossman, Nwanneka Okwundu, Edmund K. Bartlett, Michael A. Marchetti, Megan Othus
JAMA Dermatology. 2020-09-01 - 683 citationsCombined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled...F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann
The Lancet. Oncology. 2016-11-01 - 37 citationsAssessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenibA. Benjamin Suttle, Kenneth F. Grossmann, Daniele Ouellet, Lauren E. Richards-Peterson, Gursel Aktan
Journal of Clinical Pharmacology. 2015-04-01
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk MelanomaJune 8th, 2021- SWOG Researchers to Present Practice-Changing Research at Virtual ASCO 2021June 1st, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
